CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Incidence and Survival by Human Epidermal Growth Factor Receptor-2 Status in Young Women with Stage I-III Breast Cancer: SEER 2010–2016
-
8 2020
-
-
Source: Clin Breast Cancer. 20(4):e410-e422
[PDF-425.81 KB]
Details:
-
Alternative Title:Clin Breast Cancer
-
Personal Author:
-
Description:Background:
Young, premenopausal women with breast cancer often experience more aggressive disease biology and poorer survival than older women. Diagnostic and therapeutic advances, including human epidermal growth factor receptor-2 (HER2)-directed therapy, may lessen treatment burden and improve survival for these young women, but contemporary incidence and survival data by HER2 status are limited.
Patients and Methods:
We identified women aged 20–49 years (n=68,530) diagnosed with stage I-III breast cancer during 2010–2016 from the United States Surveillance, Epidemiology and End Results 18 registries database. Age-adjusted, average annual percentage changes in incidence (diagnosis 2010–2016) and five-year Kaplan-Meier survival curves (diagnosis 2010–2015) were estimated by HER2 and hormone receptor (HR) status and stratified independently by cancer stage and race/ethnicity.
Results:
With increasing age decade, proportions of HER2−/HR+ cancer increased, whereas proportions of HER2+/HR+, HER2+/HR−, and HER2−/HR− decreased. The greatest increases in incidence during 2010–2016 were observed for HER2+ among women 20–49 and HER2−/HR− among women 20–29. Incidence decreased for HER2−/HR− among women 40–49. Five-year survival was lowest for HER2−/HR− status compared to other receptor-based subtypes among women 20–49. HER2+ status was more beneficial for five-year survival than HR+ status among women 20–29, with the opposite observed among women 30–49, particularly those 40–49.
Conclusions:
HER2+ breast cancer increased among premenopausal women and was also associated with higher early survival within each HR status. HER2−/HR− cancer also increased among women 20–29 and was associated with lower early survival. Our contemporary data provide important insights to help inform preventive and therapeutic strategies for premenopausal women.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:32278642
-
Pubmed Central ID:PMC7398833
-
Document Type:
-
Funding:
-
Volume:20
-
Issue:4
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
